Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iSCORE: Nivolumab and Relatlimab in mCRC
NCT03867799Phase 2Active, not recruiting
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Mar 2019
- Primary completion
- Oct 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of relatlimab in metastatic colorectal cancer (mCRC), sponsored by Royal Marsden NHS Foundation Trust. Started Mar 2019; status: active, not recruiting.
02
Drugs
relatlimab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03867799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03867799.